Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference. CEO Troy Wilson is set to present on August 11, 2020, at 2:20 p.m. ET. The conference runs from August 11-12, 2020, and a live audio webcast will be available on the company’s website. Kura’s pipeline includes two drug candidates targeting cancer pathways, with tipifarnib in a pivotal trial for HRAS mutant head and neck cancer and KO-539 in Phase 1/2A trials for acute myeloid leukemia.

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned, small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When is Kura Oncology's presentation at the 2020 Wedbush PacGrow Healthcare Virtual Conference?

Kura Oncology's presentation is scheduled for August 11, 2020, at 2:20 p.m. ET.

What is Kura Oncology's most advanced drug candidate?

Kura Oncology's most advanced drug candidate is tipifarnib, targeting HRAS mutant head and neck squamous cell carcinoma.

Where can I listen to Kura's conference presentation?

You can access the live audio webcast of Kura's presentation on their website in the Investors section.

What are Kura Oncology's drug candidates currently in clinical trials?

Kura is developing tipifarnib and KO-539, with trials for HRAS mutant head and neck cancer and acute myeloid leukemia, respectively.

How long will the conference be available for replay?

The archived replay of Kura's presentation will be available for 30 days following the event.